{"id":"lansoprazole-triple-therapy","safety":{"commonSideEffects":[{"rate":"7.1%","effect":"Headache"},{"rate":"5.7%","effect":"Diarrhea"},{"rate":"4.9%","effect":"Nausea"},{"rate":"4.5%","effect":"Abdominal pain"},{"rate":"3.6%","effect":"Dizziness"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This leads to a decrease in gastric acid secretion, which helps to heal and prevent ulcers.","oneSentence":"Inhibits the H+/K+ ATPase enzyme in the gastric parietal cells","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:41:32.542Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Gastroesophageal reflux disease"},{"name":"Peptic ulcer disease"}]},"trialDetails":[{"nctId":"NCT07344506","phase":"PHASE4","title":"CURE-H. Pylori: A Trial on the Combination of Anti-Ulcerants and Levofloxacin-Based Therapy for Helicobacter Pylori Eradication","status":"RECRUITING","sponsor":"Dow University of Health Sciences","startDate":"2025-05-01","conditions":"H. Pylori Gastrointestinal Disease, H.Pylori Infection, H.Pylori Eradication Rate","enrollment":942},{"nctId":"NCT06964334","phase":"PHASE3","title":"The Effect of Vitamin D Supplement as Adjuvant Therapy in Eradication of Helicobacter Pylori Infection","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2025-06-01","conditions":"Helicobacter Pylori Infection","enrollment":70},{"nctId":"NCT01678027","phase":"PHASE3","title":"Gastric Cancer Prevention in the Family Members by Helicobacter Pylori Eradication","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Center, Korea","startDate":"2004-11","conditions":"Gastric Cancer, Helicobacter Pylori Infection, Family Members","enrollment":1838},{"nctId":"NCT05371249","phase":"PHASE4","title":"Vonoprazan-Based Triple Therapy in Comparison With Extended Sequential Therapy","status":"UNKNOWN","sponsor":"Fu Jen Catholic University Hospital","startDate":"2021-12-01","conditions":"Helicobacter Pylori","enrollment":628},{"nctId":"NCT05933031","phase":"PHASE2","title":"Exploratory Study to Standard Triple Therapy With Tegoprazan(by Dose) in H. Pylori Positive Patients","status":"UNKNOWN","sponsor":"HK inno.N Corporation","startDate":"2023-02-27","conditions":"Helicobacter Pylori Infection","enrollment":381},{"nctId":"NCT05861687","phase":"PHASE2, PHASE3","title":"Recurrence Rate Comparison Between Esomeprazole and Lansoprazole in Eradicating Helicobacter Pylori Infection Among Children","status":"COMPLETED","sponsor":"Finni Kollins","startDate":"2021-08-01","conditions":"Helicobacter Pylori Infection","enrollment":51},{"nctId":"NCT04713670","phase":"PHASE4","title":"Comparison of Vonoprazan-based Versus Lansoprazole-based Triple Therapy, High Dose Dual Therapy, Bismuth and Non-bismuth Quadruple Therapy in the First-line Treatment of Helicobacter Pylori Infection","status":"RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2021-03-10","conditions":"H. Pylori Infection","enrollment":1200},{"nctId":"NCT04167670","phase":"PHASE3","title":"Efficacy and Safety of Vonoprazan Compared to Lansoprazole in Participants With Helicobacter Pylori Infection","status":"COMPLETED","sponsor":"Phathom Pharmaceuticals, Inc.","startDate":"2019-12-10","conditions":"Helicobacter Pylori Infection","enrollment":1046},{"nctId":"NCT05184491","phase":"PHASE4","title":"Nitazoxanide and Lansoprazole Based Regimens for H. Pylori Management","status":"UNKNOWN","sponsor":"National Liver Institute, Egypt","startDate":"2021-10-15","conditions":"Helicobacter Pylori","enrollment":500},{"nctId":"NCT03317223","phase":"PHASE3","title":"A Phase 3 Study to Evaluate the Efficacy and Safety of Triple Therapy With CJ-12420 in H. Pylori Positive Patients","status":"COMPLETED","sponsor":"HK inno.N Corporation","startDate":"2017-10-17","conditions":"Helicobacter Pylori Infection","enrollment":350},{"nctId":"NCT03498456","phase":"PHASE3","title":"Triple Therapy With Tegoprazan in H. Pylori Positive Patients","status":"COMPLETED","sponsor":"HK inno.N Corporation","startDate":"2018-06-28","conditions":"Helicobacter Pylori Infection","enrollment":284},{"nctId":"NCT02557932","phase":"PHASE3","title":"Comparison of 7-day PPI-based Standard Triple Therapy and 10-day Bismuth Quadruple Therapy for H. Pylori Eradication","status":"COMPLETED","sponsor":"National Cancer Center, Korea","startDate":"2015-09","conditions":"Helicobacter Pylori Infection, Family History of Stomach Cancer","enrollment":352},{"nctId":"NCT03837990","phase":"","title":"One Sequencing Find All for Helicobacter Pylori Infection","status":"UNKNOWN","sponsor":"Seoul National University Hospital","startDate":"2019-05-01","conditions":"Helicobacter Pylori Infection, Resistant Infection","enrollment":60},{"nctId":"NCT03516669","phase":"PHASE4","title":"Intraluminal Clarithromycin Powder Monotherapy for Helicobacter Pylori Infection","status":"COMPLETED","sponsor":"Mackay Memorial Hospital","startDate":"2018-05-07","conditions":"Helicobacter Pylori Infection","enrollment":20},{"nctId":"NCT03524833","phase":"PHASE4","title":"Intraluminal Metronidazole Powder Monotherapy for Helicobacter Pylori Infection","status":"COMPLETED","sponsor":"Mackay Memorial Hospital","startDate":"2018-05-07","conditions":"Helicobacter Pylori Infection","enrollment":20},{"nctId":"NCT03654781","phase":"PHASE1","title":"Impact of Periodontal Treatment on Gastric Helicobacter Pylori Eradication","status":"COMPLETED","sponsor":"Ondokuz Mayıs University","startDate":"2008-04-21","conditions":"Helicobacter Pylori Infection","enrollment":98},{"nctId":"NCT03571230","phase":"PHASE4","title":"Antimicrobial Susceptibility Testing Guided Therapy Versus Empirical Therapy for the First-line Helicobacter Pylori Eradication.","status":"UNKNOWN","sponsor":"Shandong University","startDate":"2018-07-01","conditions":"Helicobacter Pylori Infection, Antimicrobial Susceptibility Testing","enrollment":400},{"nctId":"NCT03124420","phase":"PHASE4","title":"Intraluminal Therapy for Helicobacter Pylori Infection","status":"COMPLETED","sponsor":"Mackay Memorial Hospital","startDate":"2017-04-28","conditions":"Helicobacter Pylori Infection","enrollment":100},{"nctId":"NCT01906879","phase":"PHASE4","title":"Triple Therapy Versus Quadruple Therapies in the First Line Therapy of Helicobacter Pylori Infection","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2013-06","conditions":"Helicobacter Pylori Infection","enrollment":1620},{"nctId":"NCT02711176","phase":"PHASE4","title":"Comparison of Daily Single Dose Triple and Conventional Triple Therapies for Helicobacter Pylori Infection","status":"COMPLETED","sponsor":"Zahra Vahdat Shariatpanahi","startDate":"2016-09","conditions":"Helicobacter Infection","enrollment":212},{"nctId":"NCT02726269","phase":"PHASE3","title":"Triple Therapy Versus Levofloxacin-based Therapy for Helicobacter Pylori Eradication in Mexico.","status":"COMPLETED","sponsor":"Asofarma de México S.A de C.V.","startDate":"2012-06","conditions":"Helicobacter Pylori Gastritis","enrollment":230},{"nctId":"NCT02682446","phase":"","title":"The Efficacy of Serum Pepsinogen for Prediction of Metachronous Gastric Neoplasm","status":"COMPLETED","sponsor":"Kyungpook National University Hospital","startDate":"2007-01","conditions":"Gastric Cancer","enrollment":800},{"nctId":"NCT02541786","phase":"PHASE4","title":"Comparison of Dexlansoprazole-based Triple and Rabeprazole-based Triple Therapies for Helicobacter Pylori Infection","status":"COMPLETED","sponsor":"Kaohsiung Medical University","startDate":"2015-01","conditions":"Helicobacter Pylori Infection","enrollment":177},{"nctId":"NCT01481844","phase":"PHASE3","title":"Sequential Therapy Versus Quadruple Therapy as Second Line Treatment After Failure of the Standard Triple Therapy for H Pylori Infection","status":"COMPLETED","sponsor":"Soroka University Medical Center","startDate":"2011-11","conditions":"Optimization of Second Line Treatment Protocol for H Pylori Eradication","enrollment":101},{"nctId":"NCT01418300","phase":"PHASE4","title":"Comparison of Conventional Triple Therapy Versus Sequential Therapy for H. Pylori in Peptic Ulcer Disease: Prospective Randomized Trial","status":"COMPLETED","sponsor":"Jun-Won Chung","startDate":"2010-08","conditions":"Helicobacter Infected Patients","enrollment":159},{"nctId":"NCT01888237","phase":"PHASE4","title":"High Dose PPI Triple Therapy Versus Sequential Therapy for Helicobacter Pylori Eradication","status":"COMPLETED","sponsor":"Mahidol University","startDate":"2013-05","conditions":"Dyspepsia, Helicobacter-associated Gastritis, Stomach Disorders","enrollment":118},{"nctId":"NCT01537055","phase":"PHASE4","title":"Comparison of the Efficacy of Levofloxacin-based Sequential Therapy and Triple Therapy as Second Line Therapy","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2012-02","conditions":"Eradication Rate for Helicobacter","enrollment":600},{"nctId":"NCT02249546","phase":"PHASE4","title":"Efficacy of Acetylcysteine-containing Triple Therapy in the First Line of Helicobacter Pylori Infection","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2014-09","conditions":"Helicobacter Pylori Infection","enrollment":654},{"nctId":"NCT01505127","phase":"PHASE3","title":"Efficacy of TAK-438, Amoxicillin and Clarithromycin in the First Line Eradication of H. Pylori","status":"COMPLETED","sponsor":"Takeda","startDate":"2012-01","conditions":"H. Pylori Infection","enrollment":650},{"nctId":"NCT01607918","phase":"PHASE4","title":"Clarithromycin-based Triple Therapy for 14 Days Versus Sequential Therapy 10 Days in the First Line Therapy","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2012-02","conditions":"Eradication Rates of the Two Regimens","enrollment":1300},{"nctId":"NCT01922505","phase":"","title":"Eradication Rates of Helicobacter Pylori and Its Affecting Factors","status":"COMPLETED","sponsor":"Seoul National University Bundang Hospital","startDate":"2003-01","conditions":"Helicobacter Infections","enrollment":2500},{"nctId":"NCT01667718","phase":"PHASE4","title":"Bismuth Improves the Efficacy of Levofloxacin-containing Triple Therapy for Helicobacter Pylori Treatment","status":"COMPLETED","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2012-05","conditions":"Functional Dyspepsia, Peptic Ulcer","enrollment":161},{"nctId":"NCT01042184","phase":"PHASE4","title":"Efficacy of 10-day and 14-day Sequential Therapy Versus Triple Therapy on the Eradication of Helicobacter Pylori","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2009-12","conditions":"H. Pylori Infection","enrollment":900},{"nctId":"NCT01131026","phase":"PHASE3","title":"Efficacy and Safety Evaluation of Levofloxacin Triple Therapy for Helicobacter Pylori Eradication","status":"COMPLETED","sponsor":"Deva Holding A.S.","startDate":"2010-06","conditions":"Helicobacter Pylori Infection","enrollment":60},{"nctId":"NCT00816140","phase":"PHASE4","title":"Levofloxacin Versus Clarithromycin Triple Therapy in First-Line Treatment for Helicobacter Pylori Eradication","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2007-06","conditions":"Helicobacter Infections","enrollment":432},{"nctId":"NCT00281047","phase":"PHASE2, PHASE3","title":"The Influence of FP-10 on the Eradication Rates of H. Pylori by a Triple Therapy","status":"UNKNOWN","sponsor":"Hamamatsu University","startDate":"2006-01","conditions":"Helicobacter Pylori","enrollment":138}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":12,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Lansoprazole Triple Therapy","genericName":"Lansoprazole Triple Therapy","companyName":"HK inno.N Corporation","companyId":"hk-inno-n-corporation","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Inhibits the H+/K+ ATPase enzyme in the gastric parietal cells Used for Gastroesophageal reflux disease, Peptic ulcer disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}